



Universiteit
Leiden
The Netherlands

Migraine and brain changes

Meinders, I.H.

Citation

Meinders, I. H. (2018, February 15). *Migraine and brain changes*. Retrieved from <https://hdl.handle.net/1887/61147>

Version: Not Applicable (or Unknown)

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/61147>

Note: To cite this publication please use the final published version (if applicable).

Cover Page



Universiteit Leiden



The following handle holds various files of this Leiden University dissertation:
<http://hdl.handle.net/1887/61147>

Author: Meinders, I.H.

Title: Migraine and brain change

Issue Date: 2018-02-15

Chapter 3

Iron accumulation in migraine

Inge H. Palm-Meinders
Michel D. Ferrari
Mark C. Kruit

Palm-Meinders, I.H. (2012). Iron accumulation in migraine. In D. Borsook (Ed.), *The Migraine Brain* (pp. 117-122). Oxford

IRON HOMEOSTASIS

Iron plays an important role in many biochemical processes. In general, iron is essential for proper functioning of the body due to its involvement in oxygen transport, oxygen storage, transportation of electrons, glucose metabolism, synthesis of neurotransmitters and myelin, and DNA replication [Connor and Benkovic, 1992;Kell, 2009;Rouault and Cooperman, 2006]. The body needs to maintain iron concentrations stable, because iron shortage as well as iron excess lead to dysfunction. Excess of iron is harmful because of its role in the formation of highly reactive hydroxyl radicals, which cause damage to all components of a cell, including proteins, lipids, and DNA. The imbalance between reactive oxygen species and the ability of the body to detoxify the reactive intermediates, or to repair the resulting damage, is called oxidative stress. Oxidative stress is involved in many diseases, including neurological diseases. To prevent an excess of iron, the body regulates the amount of it by changes in uptake, storage and release in relation to its need. Recently, the protein hepcidin was found to play an important role in this process of iron homeostasis by regulating intestinal iron absorption [Ganz and Nemeth, 2011]. Ferritin is the protein that serves to store iron in a soluble and non-toxic form, to deposit it in a safe form, and to transport it to areas where it is required [Maguire et al., 1982]. Ferritin is also involved as a delivery protein in the brain [Hulet et al., 1999] and is especially present in larger concentration in the basal ganglia [Aquino et al., 2009]. Iron is important for the brain, as the brain requires relative much energy and iron is an essential component of ATP synthesis [Gordon, 2003]. In addition, iron is essential for the production of lipids and cholesterol and is therefore important in the synthesis and metabolism of myelin and neurotransmitters [Levenson and Tassabehji, 2004;Thomas and Jankovic, 2004]. Brain iron homeostasis is different from other organs because of several brain specific characteristics. First, brain tissue is protected from free influx of iron from the plasma by the blood brain barrier [Burdo et al., 2003;Burdo and Connor, 2003]. This barrier, together with the ventricular system, actively regulates iron transportation by transferring receptors on capillary endothelial cells[Connor, 1994] as well as on endothelial cells of the choroid plexus [Moos, 1996]. Second, the concentration of iron varies between different parts of the brain. Brain regions with motor function (extrapyramidal regions) contain more iron than non-motor parts [Koeppen et al., 1995].

IRON AND THE BRAIN

In 1922, Spatz already recorded the distribution of iron in the different areas of the brain by immersion of brain slices in a staining solution (Perl's stain or the Prussian Blue stain). Today, iron in the brain can be detected by using magnetic resonance imaging (MRI) and is visible on T2-weighted and T2*-weighted images as hypointensity caused

by field heterogeneity and magnetic susceptibility effects [Drayer et al., 1986a;Haacke et al., 2005]. A higher load of iron is associated with more hypointensity on the MR image [Haacke et al., 2005;Schenck, 1995]. Recent evidence shows a good correlation between conclusions on iron distribution in brain areas from post-mortem data and MR imaging [Peran et al., 2009a]. In adults, the largest concentration of iron is found in the globus pallidus, red nucleus, substantia nigra (including pars reticularis), followed by caudate nucleus and putamen. By staining of brain slices as well as by MR imaging, infants have demonstrated to have only minimal concentrations of iron in the brain [Diezel PD, 1955;Drayer et al., 1986b]. The increase in iron concentration in the brain is speculated to be associated with a change in vascularisation [Faucheux et al., 1999]. Age-specific iron accumulation in the human brain has been described as early as in 1958, by Hallgren [Hallgren and Sourander, 1958]. He already demonstrated, by staining of brain slices, an increase of especially ferritin in specific brain structures, including the globus pallidus and putamen as preferred sites during the first three decades of human life [Hallgren and Sourander, 1958]. More recent post-mortem studies have shown higher ferritin levels at older age in several basal ganglia, including caudate nucleus, putamen, substantia nigra, and globus pallidus [Connor et al., 1995;Zecca et al., 2001]. These findings have been confirmed by MR imaging results, demonstrating age-related iron increase among these basal ganglia [Bartzokis et al., 1997]. Two recent MRI studies on changes in brain iron concentration related to aging show an increase of iron in all basal ganglia with increasing age, with specific age-related iron deposition patterns for the different structures [Cherubini et al., 2009;Peran et al., 2009b]. For instance, the globus pallidus shows a clear increase of iron concentration from childhood into adulthood. Substantia nigra already contains more iron than the globus pallidus at younger age and increase follows a steeper curve, whereas both putamen and caudate nucleus show a much slower rate of iron increase with aging [Aquino et al., 2009]. Furthermore, iron increase follows a precise accumulation direction from posterior to anterior and from medial to lateral parts of the basal ganglia [Aquino et al., 2009]. Below the age of 15 years, iron accumulation is largest in the medial part of the internal globus pallidus, whereas it is largest in the lateral part between the ages of 15-30 years of age [Aquino et al., 2009]. Mechanisms responsible for early accumulation in the substantia nigra and globus pallidus are not clear, but it could be the result of preferential or abnormal local neuronal uptake of iron [Bartzokis et al., 1997], abnormal transportation of iron along white matter pathways connecting these nuclei [Drayer et al., 1986a;Aoki et al., 1989] or it is based on a decreased efficiency of the usual iron transport from the basal ganglia to areas elsewhere due to age-related loss of neurons [Dietrich and Bradley, Jr., 1988;Cross et al., 1990]. After the age of 50 years, all basal ganglia show a large variability between subjects for hypointensity on MRI, because the T2 values of deep nuclei are significantly influenced by non-iron-related tissue changes, such as myelin loss or an increase in water content associated with microvascular changes [Aquino et al., 2009;Bartzokis et al., 1997;Schenker et al., 1993]. Despite the large variability of brain

iron accumulation among elderly subjects, it has been suggested that if hypointensity is found in the caudate nucleus, this could be a sign of central nervous system disease instead of being part of a normal aging process [Milton et al., 1991]. This was confirmed by a recent MRI study among elderly subjects which described presence of hypointensity of the caudate nucleus to be associated with the presence of a higher load of age-related cerebral changes, like more atrophy and a higher load of white matter hyperintensities [van Es et al., 2008]. Iron excess in the basal ganglia is damaging, because it increases the tissue's susceptibility for apoptosis and inflammation, it could lead to basal ganglia dysfunction due to decreased protein synthesis, and the tissue becomes more vulnerable for the damaging effect of reactive oxygen species. This destructive process is being summarized by Zecca as iron accumulation, invasion and increased reactivity [Zecca et al., 2004].

IRON AND NEUROLOGICAL DISORDERS

Increased iron levels in pathological relevant brain structures and iron-mediated oxidative stress are associated with several neurological disorders, including Parkinson disease, Alzheimer disease, Huntington disease, Friedreich ataxia, Amyotrophic Lateral Sclerosis, Neurodegeneration with Brain Iron Accumulation (formerly Hallervorden-Spatz syndrome), and also migraine. Every disorder has its specific mechanisms and locations of brain iron accumulation.

In Parkinson disease, iron excess has been demonstrated in the substantia nigra [Sian-Hulsmann et al., 2010;Kell, 2010;Bartzokis et al., 1997;Sian-Hulsmann et al., 2010;Kell, 2010;Gotz et al., 1990;Gorell et al., 1995;Ryvlin et al., 1995] and was found to be associated with local oxidative stress, as indicated by protein disruption [Goodwin et al., 2000] and oxidative DNA damage [Sanchez-Ramos et al., 1987;Alam et al., 1997;Poon et al., 2004a;Poon et al., 2004b].

In the brains of patients suffering from Alzheimer disease, iron accumulation occurs without the normal age-related increase in ferritin, thereby increasing the risk of oxidative stress [Zecca et al., 2004]. Iron excess is found early in the disease process in several brain structures, including the basal ganglia [Connor and Benkovic, 1992;Bartzokis et al., 1997;Bartzokis and Tishler, 2000;Bartzokis et al., 2000]. Although the origin of elevated brain iron levels is unclear, the role of iron is apparent: both senile plaques and neurofibrillary tangles, characteristic for the disease, have been shown to accumulate iron [Good et al., 1992;Levine, 1997;Sayre et al., 2000;Rottkamp et al., 2000]

In Huntington disease, iron accumulation has been demonstrated in the putamen, caudate nucleus, and globus pallidus by post-mortem studies and MRI studies [Bartzokis and Tishler, 2000;Chen et al., 1993;Dexter et al., 1992;Rutledge et al., 1987]. The iron excess contributes to oxidative stress, as indicated by protein disruption [Marnett,

2000;Stadtman, 2001] and oxidative DNA damage[Alam et al., 1997;Marnett, 2000; Poon et al., 2004a;Sanchez-Ramos et al., 1987].

Friedreich ataxia was first described by the German physician Nikolaus Friedreich in 1860 [Friedreich, 1863] and is marked by a genetic mutation causing the mitochondrial protein frataxin to be lacking, leading to impaired iron export from the mitochondria, cytoplasmic depletion, induction of plasma membrane proteins involved in iron uptake, and consequent iron overload [Berg and Youdim, 2006], including excess of iron in the dentate nucleus [Koeppen et al., 2007;Waldvogel et al., 1999].

In Amyotrophic Lateral Sclerosis (ALS), increased serum levels of ferritin have been reported [Goodall et al., 2008] and MR images of the brains of ALS patients show iron accumulation in the dentate nucleus [Langkammer et al., 2010]. Although origin of iron excess in ALS is not yet clear, increased oxidative damage to DNA, lipids, and proteins can be seen early in the disease process, which makes it plausible that iron is at least partly involved [Berg and Youdim, 2006].

Brain MRI evaluation of patients suffering from Neurodegeneration with Brain Iron Accumulation usually show iron accumulation in the globus pallidus (typical but non-specific eye-of-the-tiger sign), the substantia nigra, and the dentate nucleus [Savoirdo et al., 1993;Hayflick et al., 2003;Swaiman, 1991;Halliday, 1995] and histopathology demonstrates iron excess accompanied by neuronal loss and gliosis [Savoirdo et al., 1993;Galvin et al., 2000]. It is proposed that accumulation of cysteine, which chelates iron, causes oxidative stress and leads to the increase of iron in the basal ganglia [Berg and Youdim, 2006;Perry et al., 1985].

IRON AND MIGRAINE

Few studies have been published describing the association between migraine and iron levels in the brain. After earlier reports describing functional blood oxygenation level-dependent MR imaging demonstrating the involvement in pain of several specific brain structures, Welch and colleagues focused their attention on the periaqueductal grey matter, red nucleus and substantia nigra in relation to migraine [Welch et al., 2001]. It was speculated that, since these brain structures in particular show high iron levels and are densely populated with neurotransmitters that can generate free radicals, repeated migraine attacks and associated repeated hypoxia could result in release of free radicals and cell damage. This mechanism could be seen in those brain areas as accumulation of iron, similar to the processes already known in other neurodegenerative diseases as mentioned above.

To test this hypothesis, a clinic-based cross-sectional brain MRI study was carried out to assess iron levels by measuring transverse relaxation rates [Welch et al., 2001]. This study included seventeen migraine patients, diagnosed using International Headache Society (IHS) criteria, seventeen patients with chronic daily headache, and seven-

teen control participants; aged 20-64 years. Compared with controls, significant higher iron levels were found in the periaqueductal grey matter of the migraine and chronic daily headache patients. No differences were found between men and women, nor between migraine with and without aura. In addition, an association between iron accumulation and illness duration was found.

Because no relation was found between increased iron levels and age in this study, authors speculated that iron accumulation must be related to repeated headache attacks. Several explanations for the high iron content of the periaqueductal grey matter among migraineurs were given by the authors. First, as a result of the migraine related pain combined with oxidative stress, this structure could be abnormal highly metabolic active in migraineurs, since transferring-receptor binding is proportional to the metabolic activity of the neuron, and in turn may be influenced by nociceptive function. Overexpression of transferrin receptors might result in iron accumulation and free radical cell damage, a process that may be aggravated by eventual hypoperfusion during migraine attacks. As a consequence, metabolism and iron uptake in the remaining neurons would be increased, leading to even more iron accumulation. Second explanation for high iron concentration is the presence of gliosis, since glial cells have high iron content, but the authors found no evidence of gliosis on MR images of these participants. From this study, it was concluded that iron accumulation in the periaqueductal grey matter among migraineurs was the result of an impaired iron homeostasis, possibly associated with neuronal dysfunction or damage [Welch et al., 2001].

To evaluate these interesting findings in a larger, population-based group of migraineurs, brain MR images of 138 migraineurs (IHS criteria) and 75 matched controls were analyzed for iron concentration in deep brain nuclei as part of the CAMERA-study (Cerebral Abnormalities in Migraine, an Epidemiological Risk Analysis) [Kruit et al., 2009]. Because measurements in older subjects are increasingly influenced by non-iron related factors, analyses were separated into subjects younger than 50 years and older than 50 years. In the younger group, compared to controls, migraineurs demonstrated higher iron concentrations in several nuclei, including putamen, globus pallidus, and red nucleus. No differences were found between men and women, nor between migraine with and without aura. Among these participants under 50 years, an association was found between longer migraine duration and higher iron concentration in putamen, caudate nucleus, and red nucleus [Kruit et al., 2009]. These structures are all known to be involved in the normal central nociceptive network [Iadarola et al., 1998].

Data from both studies suggest that repeated migraine attacks, or the accompanying pain, are associated with higher iron concentration in several brain structures involved in central pain processing and migraine pathology. It is not known whether the increase in iron is caused by repetitive activation of the pain nuclei or whether the increased iron itself inflicts damage to these structures via free radicals in oxidative stress. Furthermore, theoretically, damage of these pain-processing nuclei could lead to chronicification of migraine in specific patients. As to date, studies on this subject have a cross-

sectional design, the assumption that recurring attacks lead to accumulation of iron can not be verified. A longitudinal study is needed to follow-up on migraineurs and controls to carefully evaluate their general health status, headache history, course of migraine over the years, and measurements of brain iron concentration.

SUMMARY

During aging, iron accumulates in the brain, specifically in the basal ganglia, following a certain distribution pattern. Iron accumulation could be the result of neuronal loss, followed by substitution by cells with higher iron loads, or of leakage of the blood brain barrier, allowing iron to access the brain in higher concentration. Several neurological disorders, as well as migraine, are associated with iron excess in the brain. Higher brain iron concentration generates a reactive iron overload, which invades and damages neurons and other cells. It is not clear yet whether iron accumulation in basal ganglia plays a primary or secondary role in the pathogenesis.

REFERENCES

Alam ZI, Jenner A, Daniel SE, Lees AJ, Cairns N, Marsden CD, Jenner P, and Halliwell B. 1997. Oxidative DNA damage in the parkinsonian brain: an apparent selective increase in 8-hydroxyguanine levels in substantia nigra. *J Neurochem* 69:1196-1203.

Aoki S, Okada Y, Nishimura K, Barkovich AJ, Kjos BO, Brasch RC, and Norman D. 1989. Normal deposition of brain iron in childhood and adolescence: MR imaging at 1.5 T. *Radiology* 172:381-385.

Aquino D, Bizzi A, Grisoli M, Garavaglia B, Bruzzone MG, Nardocci N, Savoiaro M, and Chiapparini L. 2009. Age-related iron deposition in the basal ganglia: quantitative analysis in healthy subjects. *Radiology* 252:165-172.

Bartzokis G, Beckson M, Hance DB, Marx P, Foster JA, and Marder SR. 1997. MR evaluation of age-related increase of brain iron in young adult and older normal males. *Magn Reson Imaging* 15:29-35.

Bartzokis G, Sultzer D, Cummings J, Holt LE, Hance DB, Henderson VW, and Mintz J. 2000. In vivo evaluation of brain iron in Alzheimer disease using magnetic resonance imaging. *Arch Gen Psychiatry* 57:47-53.

Bartzokis G and Tishler TA. 2000. MRI evaluation of basal ganglia ferritin iron and neurotoxicity in Alzheimer's and Huntington's disease. *Cell Mol Biol (Noisy -le-grand)* 46:821-833.

Berg D and Youdim MB. 2006. Role of iron in neurodegenerative disorders. *Top Magn Reson Imaging* 17:5-17.

Burdo JR, Antonetti DA, Wolpert EB, and Connor JR. 2003. Mechanisms and regulation of transferrin and iron transport in a model blood-brain barrier system. *Neuroscience* 121:883-890.

Burdo JR and Connor JR. 2003. Brain iron uptake and homeostatic mechanisms: an overview. *Biometals* 16:63-75.

Chen JC, Hardy PA, Kucharczyk W, Clauberg M, Joshi JG, Vourlas A, Dhar M, and Henkelman RM. 1993. MR of human postmortem brain tissue: correlative study between T2 and assays of iron and ferritin in Parkinson and Huntington disease. *AJNR Am J Neuroradiol* 14:275-281.

Cherubini A, Peran P, Caltagirone C, Sabatini U, and Spalletta G. 2009. Aging of subcortical nuclei: microstructural, mineralization and atrophy modifications measured in vivo using MRI. *Neuroimage* 48:29-36.

Connor JR. 1994. Iron regulation in the brain at the cell and molecular level. *Adv Exp Med Biol* 356:229-238.

Connor JR and Benkovic SA. 1992. Iron regulation in the brain: histochemical, biochemical, and molecular considerations. *Ann Neurol* 32 Suppl:S51-S61.

Connor JR, Snyder BS, Arosio P, Loeffler DA, and LeWitt P. 1995. A quantitative analysis of iso-ferritins in select regions of aged, parkinsonian, and Alzheimer's diseased brains. *J Neurochem* 65:717-724.

Cross PA, Atlas SW, and Grossman RI. 1990. MR evaluation of brain iron in children with cerebral infarction. *AJNR Am J Neuroradiol* 11:341-348.

Dexter DT, Jenner P, Schapira AH, and Marsden CD. 1992. Alterations in levels of iron, ferritin, and other trace metals in neurodegenerative diseases affecting the basal ganglia. *The Royal Kings and Queens Parkinson's Disease Research Group. Ann Neurol* 32 Suppl:S94-100.

Dietrich RB and Bradley WG, Jr. 1988. Iron accumulation in the basal ganglia following severe ischemic-anoxic insults in children. *Radiology* 168:203-206.

Diezel PD. 1955. Iron in the brain: a chemical and histochemical examination. In: Waelsch H, ed. *Biochemistry of the developing nervous system*. New York: Academic Press.

Drayer B, Burger P, Darwin R, Riederer S, Herfkens R, and Johnson GA. 1986a. MRI of brain iron. *AJR Am J Roentgenol* 147:103-110.

Drayer BP, Olanow W, Burger P, Johnson GA, Herfkens R, and Riederer S. 1986b. Parkinson plus syndrome: diagnosis using high field MR imaging of brain iron. *Radiology* 159:493-498.

Faucheux BA, Bonnet AM, Agid Y, and Hirsch EC. 1999. Blood vessels change in the mesencephalon of patients with Parkinson's disease. *Lancet* 353:981-982.

Friedreich N. Über degenerative Atrophie der spinalen Hinterstränge. *Virchows Archiv für pathologische Anatomie und Physiologie und für klinische Medizin*. 26, 391-419. 1863. Berlin.

Ref Type: Generic

- Galvin JE, Giasson B, Hurtig HI, Lee VM, and Trojanowski JQ. 2000. Neurodegeneration with brain iron accumulation, type 1 is characterized by alpha-, beta-, and gamma-synuclein neuropathology. *Am J Pathol* 157:361-368.
- Ganz T and Nemeth E. 2011. Hepcidin and disorders of iron metabolism. *Annu Rev Med* 62:347-360.
- Good PF, Perl DP, Bierer LM, and Schmeidler J. 1992. Selective accumulation of aluminum and iron in the neurofibrillary tangles of Alzheimer's disease: a laser microprobe (LAMMA) study. *Ann Neurol* 31:286-292.
- Goodall EF, Haque MS, and Morrison KE. 2008. Increased serum ferritin levels in amyotrophic lateral sclerosis (ALS) patients. *J Neurol* 255:1652-1656.
- Goodwin DC, Rowlinson SW, and Marnett LJ. 2000. Substitution of tyrosine for the proximal histidine ligand to the heme of prostaglandin endoperoxide synthase 2: implications for the mechanism of cyclooxygenase activation and catalysis. *Biochemistry* 39:5422-5432.
- Gordon N. 2003. Iron deficiency and the intellect. *Brain Dev* 25:3-8.
- Gorell JM, Ordidge RJ, Brown GG, Deniau JC, Buderer NM, and Helpert JA. 1995. Increased iron-related MRI contrast in the substantia nigra in Parkinson's disease. *Neurology* 45:1138-1143.
- Gotz ME, Freyberger A, and Riederer P. 1990. Oxidative stress: a role in the pathogenesis of Parkinson's disease. *J Neural Transm Suppl* 29:241-249.
- Haacke EM, Cheng NY, House MJ, Liu Q, Neelavalli J, Ogg RJ, Khan A, Ayaz M, Kirsch W, and Obenaus A. 2005. Imaging iron stores in the brain using magnetic resonance imaging. *Magn Reson Imaging* 23:1-25.
- Hallgren B and Sourander P. 1958. The effect of age on the non-haemin iron in the human brain. *J Neurochem* 3:41-51.
- Halliday W. 1995. The nosology of Hallervorden-spatz disease. *J Neurol Sci* 134 Suppl:84-91.
- Hayflick SJ, Westaway SK, Levinson B, Zhou B, Johnson MA, Ching KH, and Gitschier J. 2003. Genetic, clinical, and radiographic delineation of Hallervorden-Spatz syndrome. *N Engl J Med* 348:33-40.
- Hulet SW, Powers S, and Connor JR. 1999. Distribution of transferrin and ferritin binding in normal and multiple sclerotic human brains. *J Neurol Sci* 165:48-55.
- Iadarola MJ, Berman KF, Zeffiro TA, Byas-Smith MG, Gracely RH, Max MB, and Bennett GJ. 1998. Neural activation during acute capsaicin-evoked pain and allodynia assessed with PET. *Brain* 121 (Pt 5):931-947.
- Kell DB. 2009. Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases. *BMC Med Genomics* 2:2.
- Kell DB. 2010. Towards a unifying, systems biology understanding of large-scale cellular death and destruction caused by poorly liganded iron: Parkinson's, Huntington's, Alzheimer's, prions, bactericides, chemical toxicology and others as examples. *Arch Toxicol* 84:825-889.
- Koeppen AH, Dickson AC, and McEvoy JA. 1995. The heterogeneous distribution of brain transferrin. *J Neuropathol Exp Neurol* 54:395-403.
- Koeppen AH, Michael SC, Knutson MD, Haile DJ, Qian J, Levi S, Santambrogio P, Garrick MD, and Lamarche JB. 2007. The dentate nucleus in Friedreich's ataxia: the role of iron-responsive proteins. *Acta Neuropathol* 114:163-173.
- Kruit MC, Launer LJ, Overbosch J, van Buchem MA, and Ferrari MD. 2009. Iron accumulation in deep brain nuclei in migraine: a population-based magnetic resonance imaging study. *Cephalalgia* 29:351-359.
- Langhammer C, Enzinger C, Quasthoff S, Grafenauer P, Soellinger M, Fazekas F, and Ropele S. 2010. Mapping of iron deposition in conjunction with assessment of nerve fiber tract integrity in amyotrophic lateral sclerosis. *J Magn Reson Imaging* 31:1339-1345.
- Levenson CW and Tassabehji NM. 2004. Iron and ageing: an introduction to iron regulatory mechanisms. *Ageing Res Rev* 3:251-263.
- Levine SM. 1997. Iron deposits in multiple sclerosis and Alzheimer's disease brains. *Brain Res* 760:298-303.
- Maguire JJ, Kellogg EW, III, and Packer L. 1982. Protection against free radical formation by protein bound iron. *Toxicol Lett* 14:27-34.
- Marnett LJ. 2000. Oxyradicals and DNA damage. *Carcinogenesis* 21:361-370.
- Milton WJ, Atlas SW, Lexa FJ, Mozley PD, and Gur RE. 1991. Deep gray matter hypointensity patterns with aging in healthy adults: MR imaging at 1.5 T. *Radiology* 181:715-719.

Chapter 3

- Moos T. 1996. Immunohistochemical localization of intraneuronal transferrin receptor immunoreactivity in the adult mouse central nervous system. *J Comp Neurol* 375:675-692.
- Peran P, Cherubini A, Luccichenti G, Hagberg G, Demonet JF, Rascol O, Celsis P, Caltagirone C, Spalletta G, and Sabatini U. 2009a. Volume and iron content in basal ganglia and thalamus. *Hum Brain Mapp* 30:2667-2675.
- Peran P, Cherubini A, Luccichenti G, Hagberg G, Demonet JF, Rascol O, Celsis P, Caltagirone C, Spalletta G, and Sabatini U. 2009b. Volume and iron content in basal ganglia and thalamus. *Hum Brain Mapp* 30:2667-2675.
- Perry TL, Norman MG, Yong VW, Whiting S, Crichton JU, Hansen S, and Kish SJ. 1985. Hallervorden-Spatz disease: cysteine accumulation and cysteine dioxygenase deficiency in the globus pallidus. *Ann Neurol* 18:482-489.
- Poon HF, Calabrese V, Scapagnini G, and Butterfield DA. 2004a. Free radicals and brain aging. *Clin Geriatr Med* 20:329-359.
- Poon HF, Calabrese V, Scapagnini G, and Butterfield DA. 2004b. Free radicals: key to brain aging and heme oxygenase as a cellular response to oxidative stress. *J Gerontol A Biol Sci Med Sci* 59:478-493.
- Rottkamp CA, Nunomura A, Raina AK, Sayre LM, Perry G, and Smith MA. 2000. Oxidative stress, antioxidants, and Alzheimer disease. *Alzheimer Dis Assoc Disord* 14 Suppl 1:S62-S66.
- Rouault TA and Cooperman S. 2006. Brain iron metabolism. *Semin Pediatr Neurol* 13:142-148.
- Rutledge JN, Hilal SK, Silver AJ, Defendini R, and Fahn S. 1987. Study of movement disorders and brain iron by MR. *AJR Am J Roentgenol* 149:365-379.
- Ryvlin P, Broussolle E, Piollet H, Viallet F, Khalfallah Y, and Chazot G. 1995. Magnetic resonance imaging evidence of decreased putamenal iron content in idiopathic Parkinson's disease. *Arch Neurol* 52:583-588.
- Sanchez-Ramos JR, Hefti F, and Weiner WJ. 1987. Paraquat and Parkinson's disease. *Neurology* 37:728.
- Savoirdo M, Halliday WC, Nardocci N, Strada L, D'Incerti L, Angelini L, Rumi V, and Tesoro-Tess JD. 1993. Hallervorden-Spatz disease: MR and pathologic findings. *AJNR Am J Neuroradiol* 14:155-162.
- Sayre LM, Perry G, Atwood CS, and Smith MA. 2000. The role of metals in neurodegenerative diseases. *Cell Mol Biol (Noisy -le-grand)* 46:731-741.
- Schenck JF. 1995. Imaging of brain iron by magnetic resonance: T2 relaxation at different field strengths. *J Neurol Sci* 134 Suppl:10-18.
- Schenker C, Meier D, Wichmann W, Boesiger P, and Valavanis A. 1993. Age distribution and iron dependency of the T2 relaxation time in the globus pallidus and putamen. *Neuroradiology* 35:119-124.
- Sian-Hulsmann J, Mandel S, Youdim MB, and Riederer P. 2010. The relevance of iron in the pathogenesis of Parkinson's disease. *J Neurochem*.
- Stadtman ER. 2001. Protein oxidation in aging and age-related diseases. *Ann N Y Acad Sci* 928:22-38.
- Swaiman KF. 1991. Hallervorden-Spatz syndrome and brain iron metabolism. *Arch Neurol* 48:1285-1293.
- Thomas M and Jankovic J. 2004. Neurodegenerative disease and iron storage in the brain. *Curr Opin Neurol* 17:437-442.
- van Es AC, van der GJ, de Craen AJ, Admiraal-Behloul F, Blauw GJ, and van Buchem MA. 2008. Caudate nucleus hypointensity in the elderly is associated with markers of neurodegeneration on MRI. *Neurobiol Aging* 29:1839-1846.
- Waldvogel D, van GP, and Hallett M. 1999. Increased iron in the dentate nucleus of patients with Friedrich's ataxia. *Ann Neurol* 46:123-125.
- Welch KM, Nagesh V, Aurora SK, and Gelman N. 2001. Periaqueductal gray matter dysfunction in migraine: cause or the burden of illness? *Headache* 41:629-637.
- Zecca L, Gallorini M, Schunemann V, Trautwein AX, Gerlach M, Riederer P, Vezzoni P, and Tampellini D. 2001. Iron, neuromelanin and ferritin content in the substantia nigra of normal subjects at different ages: consequences for iron storage and neurodegenerative processes. *J Neurochem* 76:1766-1773.
- Zecca L, Youdim MB, Riederer P, Connor JR, and Crichton RR. 2004. Iron, brain ageing and neurodegenerative disorders. *Nat Rev Neurosci* 5:863-873.